Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Amgen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    752 result(s) found for: Amgen. Displaying page 1 of 38.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-004323-18 Sponsor Protocol Number: 20050130 Start Date*: 2005-11-24
    Sponsor Name:Amgen Inc.
    Full Title: An Open Label Treatment Extension Study of AMG706
    Medical condition: Subjects With Solid Tumors Previously Treated on a Seperate Amgen Protocol With AMG 706
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) SE (Completed) HU (Completed) DK (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003196-29 Sponsor Protocol Number: 20120139 Start Date*: 2018-02-07
    Sponsor Name:Amgen Inc.
    Full Title: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
    Medical condition: Any tumor type eligible for treatment with talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004774-14 Sponsor Protocol Number: AKB-6548-CI-0015 Start Date*: 2016-06-03
    Sponsor Name:Akebia Therapeutics, Inc.
    Full Title: Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chroni...
    Medical condition: Anemia in chronic kidney disease patients not on dialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) AT (Completed) CZ (Completed) ES (Completed) BG (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004265-81 Sponsor Protocol Number: AKB-6548-CI-0014 Start Date*: 2016-06-23
    Sponsor Name:Akebia Therapeutics, Inc.
    Full Title: Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney di...
    Medical condition: Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005111-51 Sponsor Protocol Number: 20170199 Start Date*: 2020-11-05
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients with Homozygous Familial Hypercholesterolemia (HoFH) in India
    Medical condition: Homozygous Familial Hypercholesterolemia (HoFH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001171-37 Sponsor Protocol Number: 20021626 Start Date*: 2012-03-07
    Sponsor Name:Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
    Full Title: A Phase IV Registry of Etanercept in Children With Juvenile Rheumatoid Arthritis
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021846-23 Sponsor Protocol Number: 20080585 Start Date*: 2010-11-24
    Sponsor Name:Amgen Inc
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Elderly Gender: Male
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-004510-33 Sponsor Protocol Number: BH17847 Start Date*: 2006-11-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, controlled, open-label, multi-center, parallel-group study to compare the efficacy and safety of RO0503821 with that of darbepoetin alfa administered intravenously at extended dosing ...
    Medical condition: Chronic renal anemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058116 Nephrogenic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) FI (Completed) BE (Completed) PT (Completed) NL (Completed) DK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001758-32 Sponsor Protocol Number: 20140114 Start Date*: 2017-08-29
    Sponsor Name:Amgen, Inc.
    Full Title: Long-term Safety Follow-up of Subjects With Giant Cell Tumour of Bone Treated With Denosumab in Study 20062004
    Medical condition: Giant Cell Tumour of Bone
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001360-11 Sponsor Protocol Number: AKB-6548-CI-0017 Start Date*: 2017-04-25
    Sponsor Name:Akebia Therapeutics, Inc.
    Full Title: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Ki...
    Medical condition: Anemia in Subjects with Incident Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) BG (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005405-37 Sponsor Protocol Number: NH19960 Start Date*: 2006-06-28
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy
    Medical condition: Anemic patients undergoing chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) CZ (Completed) EE (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000838-21 Sponsor Protocol Number: AKB-6548-CI-0016 Start Date*: 2017-04-25
    Sponsor Name:Akebia Therapeutics, Inc.
    Full Title: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects with Incident Dialys...
    Medical condition: Anemia in Subjects with Incident Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000134-37 Sponsor Protocol Number: 20010184 Start Date*: 2004-09-14
    Sponsor Name:Amgen Inc.
    Full Title: Trial to Reduce Cardiovascular Events with Aranesp Therapy
    Medical condition: Treatment of anaemia in subjects with chronic kidney disease (CKD) amd Type 2 diabetes mellitus (DM)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038444 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) LV (Completed) SE (Completed) IT (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004552-21 Sponsor Protocol Number: BH20051 Start Date*: 2007-02-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in pati...
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058124 Nephrogenic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004780-36 Sponsor Protocol Number: 20130295 Start Date*: 2016-04-22
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-001398-97 Sponsor Protocol Number: 20110118 Start Date*: 2012-10-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Co...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020604 Hypercholesterolemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) PL (Completed) GR (Completed) LT (Completed) BE (Completed) IT (Completed) NL (Completed) DK (Completed) AT (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) EE (Completed) IS (Completed) GB (Completed) DE (Completed) BG (Completed) SE (Completed) LV (Completed) IE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-002466-22 Sponsor Protocol Number: 990758 Start Date*: 2015-12-23
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open­label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-...
    Medical condition: Juvenile Rheumatoid Arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003057-30 Sponsor Protocol Number: 20190370 Start Date*: 2020-11-13
    Sponsor Name:Amgen Inc.
    Full Title: Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF
    Medical condition: Chronic heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000421-31 Sponsor Protocol Number: Etelcalcetide-T50-CKD5D-2018 Start Date*: 2018-12-19
    Sponsor Name:Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3
    Full Title: A study to investigate the influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
    Medical condition: End stage renal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001434-41 Sponsor Protocol Number: NH20052 Start Date*: 2006-11-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once every four week subcutaneous injections of RO0503821 in patients with chronic kidney dise...
    Medical condition: Chronic renal anemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058124 Nephrogenic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) SE (Prematurely Ended) GR (Completed) IT (Completed) BE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 11 14:09:03 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA